Showing results (451-460 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|August 22, 2014
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohortAntonio Di Biagio, Laura Ambra Nicolini, Patrizia Lorenzini, et al.
HIV Clinical Trials|August 22, 2014
Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trialMarina B Klein, Terry Lee, Marie-Josée Brouillette, et al.
HIV Clinical Trials|May 14, 2008
Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced diseaseF Pulido, M A Del Pozo, M Fernández-Guerrero, et al.
HIV Clinical Trials|November 29, 2007
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and womenRisa M Hoffman, Obiamiwe C Umeh, Cindy Garris, et al.
HIV Clinical Trials|February 3, 2006
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS studyR Landman, D Descamps, G Peytavin, et al.
HIV Clinical Trials|October 29, 2014
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trialEdwin DeJesus, Gerd Fätkenheuer, Catherine Orrell, et al.
HIV Clinical Trials|January 10, 2017
HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancyMarco Floridia, Giulia Masuelli, Enrica Tamburrini, et al.
HIV Clinical Trials|April 9, 2014
Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks dataA Mills, G Crofoot, R Ortiz, et al.
HIV Clinical Trials|May 14, 2008
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabineEdwin DeJesus, Peter Ruane, Cheryl McDonald, et al.
HIV Clinical Trials|February 13, 2014
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patientsLeonardo Calza, Elisa Vanino, Caterina Salvadori, et al.
Pageof 68